

**Beneficiary Advisory Panel Handout
Uniform Formulary Decisions
21 June 2007**

PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness presentations for each Uniform Formulary (UF) Class review.

Table 1: Uniform Formulary Recommendations from the May 07 DoD P&T Committee Meeting

UF Status / Implementation Period	Generic Name (Brand)	Formulations	Generics Available?
Antilipidemic II (LIP-2s)			
Formulary	Fibric Acid Derivatives		
	Fenofibrate IDD-P (micronized) (Triglide)	tab	No
	Fenofibrate micronized/nonmicronized (Lofibra)	tab/cap	Yes
	Gemfibrozil (Lopid)	tab	Yes
	Bile Acid Sequestrants (BAS)		
	Cholestyramine / aspartame (Questran Light, Prevalite)	powder	Yes
	Cholestyramine / sucrose (Questran)	powder	Yes
	Colestipol (Colestid)	tab	Yes
Non-Formulary	Fibric Acid Derivatives		
	Fenofibrate nanocrystallized (Tricor)	tab	No
	Fenofibrate micronized (Antara)	cap	No
	Omega-3 fatty acids		
	Prescription omega-3 fatty acids (Omacor)	cap	No
	Bile Acid Sequestrants (BAS)		
	Colesevelam (Welchol)	tab	No
Recommended implementation period	90 days		
5-Alpha Reductase Inhibitors (5-ARIs)			
Formulary	Finasteride (Proscar)	tab	Yes
Non-Formulary	Dutasteride (Avodart)	cap	No
Recommended implementation period	90 days		
Proton Pump Inhibitors (PPIs)			
Formulary	Omeprazole (Prilosec)	cap	Yes
	Esomeprazole (Nexium)	cap	No
Non-Formulary	Lansoprazole (Prevacid)	cap	No
	Omeprazole/sodium bicarbonate (Zegerid)	cap	No
	Pantoprazole (Protonix)	tab	No
	Rabeprazole (Aciphex)	tab	No
Recommended implementation period	90 days		

cap: capsule; IDD-P: insoluble drug delivery microparticle; tab: tablet

Table 1: Uniform Formulary Recommendations from the May 07 DoD P&T Committee Meeting (continued)

UF Status / Implementation Period	Generic Name (Brand)	Formulations	Generics Available?
Angiotensin Receptor Blockers (ARBs)			
Formulary	Candesartan (Atacand)	tab	No
	Candesartan /HCTZ (Atacand HCT)	tab	No
	Losartan (Cozaar)	tab	No
	Losartan/HCTZ (Hyzaar)	tab	No
	Telmisartan (Micardis)	tab	No
	Telmisartan/HCTZ (Micardis HCT)	tab	No
Non-Formulary	Eprosartan (Teveten)	tab	No
	Eprosartan/HCTZ (Teveten HCT)	tab	No
	Irbesartan (Avapro)	tab	No
	Irbesartan/HCTZ (Avalide)	tab	No
	Olmesartan (Benicar)	tab	No
	Olmesartan/HCTZ (Benicar HCT)	tab	No
	Valsartan (Diovan)	tab	No
Valsartan/HCTZ (Diovan)	tab	No	
Recommended implementation period	120 days		

cap; capsule; HCTZ: hydrochlorothiazide

Figure 1:




Figure 2:





Figure 3:

MHS Bile Acid Sequestrant Utilization Rxs by Drug, Oct 04 – Apr 07



Source: PDS

Table 2: Effects of Antilipidemic Drugs on Lipid Lab Parameters

Drug	TG reduction	HDL increase	LDL increase / reduction
Fibric Acid Derivatives			
Fenofibrate (Triglide, Tricor, Antara, Lofibra)	29 to 55%	11 to 23%	20% reduction (or may slightly ↑)
Gemfibrozil (Lopid, generics)	20 to 50%	15 to 20%	0 to 15% reduction (or may slightly ↑)
Prescription omega-3 fatty acid			
Omacor	30 to 50%	5 to 10%	5 to 10% increase
Bile Acid Sequestrants			
Cholestyramine (Questran, Questran Light, generics)	No change or increase	3to 5%	15 to 30% reduction
Colestipol (Colestid, generics)			
Colesevelam (Welchol)			
Statins (Zocor, Lipitor, Vytorin, Crestor, etc)	7 to 30%	5 to 15%	18 to 55% reduction
Niacin (Niaspan)	20 to 50%	15 to 35%	5 to 25% reduction

TG: triglyceride; HDL: high density lipoprotein; LDL: low density lipoprotein

Figure 4:

MHS 5-Alpha Reductase Inhibitor Utilization By Rx's, Oct 04 - Mar 07




Figure 5:

MHS PPI Utilization By Rx's, Apr 05 – Mar 07





Figure 6: Prior Authorization Process for PPI Agents Other than Omeprazole (generic) and Esomeprazole (Nexium)

TRICARE Pharmacy Network Step Therapy Process
Proton Pump Inhibitors (PPIs)



Note. OME = omeprazole (Prilosec, generics); ESO = esomeprazole (Nexium)

Figure 7: PPIs: Timeline of Previous Formulary Decisions





Figure 8

**ARBs*: MHS Utilization
Rxs by Drug, Oct 04 - Mar 07**



*HCTZ diuretic Combos follow parent ARB Source: PDTS

Table 3: Uniform Formulary Implementation Plan Summary

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification
				MTF	Retail	Mail Order		
May 07	Antilipidemic II Agents (LIP-2s)	<ul style="list-style-type: none"> fenofibrate nanocrystallized (Tricor) fenofibrate micronized (Antara) omega-3 fatty acids (Omacor) colesevelam (Welchol) 	83,612	18,849	44,402	20,361	90 days	Typical 90-day implementation period
May 07	5-Alpha Reductase Inhibitors (5-ARIs)	<ul style="list-style-type: none"> dutasteride (Avodart) 	20,917	1,087	12,830	7,000	90 days	Typical 90-day implementation period
May 07 (Update from Feb 05)	PPIs	<ul style="list-style-type: none"> lansoprazole (Prevacid) omeprazole/sodium bicarbonate (Zegerid) pantoprazole (Protonix) rabeprazole (Aciphex) 	453,525	212,130	178,120	63,275	90 days	Typical 90-day implementation period
May 07 (Update from Feb 05)	ARBs	<ul style="list-style-type: none"> eprosartan (Teveten) eprosartan HCTZ (Teveten HCT) irbesartan (Avapro) irbesartan HCTZ (Avalide) olmesartan (Benicar) olmesartan HCTZ (Benicar HCT) valsartan (Diovan) valsartan HCTZ (Diovan HCT) 	228,581	68,059	109,595	50,930	120 days	Reservations regarding ESI ability to handle implementation
Feb 07	Newer Sedative Hypnotics	<ul style="list-style-type: none"> Ramelteon (Rozerem) Zaleplon (Sonata) Zolpidem ER (Ambien CR) 	40,447	5,878	31,550	3,019	90 days	First time automated PA with step edit
Feb 07	Narcotic Analgesics	<ul style="list-style-type: none"> Tramadol ER (Ultram ER) 	1,088	0	46	1,042	90 days	Small number of beneficiaries affected

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification
				MTF	Retail	Mail Order		
Feb 07	Glaucoma Agents	<ul style="list-style-type: none"> Travoprost (Travatan, Travatan Z) Timolol maleate (Istalol) Timolol hemihydrate (Betimol) Brinzolamide (Azopt) 	17,139	1,735	12,267	3,117	90 days	Small number of beneficiaries affected
Feb 07	MAOI Antidepressants	<ul style="list-style-type: none"> Selegiline transdermal system (Emsam) 	168	0	157	11	90 days	Small number of beneficiaries affected
Nov 06	ADHD	<ul style="list-style-type: none"> Dexamethylphenidate IR (Focalin) Dexamethylphenidate SODAS (Focalin XR) Methylphenidate transdermal patch (Daytrana) 	3,078 (1.7% of patients receiving an ADHD drug)	62	2,965	51	18 Apr 07 (90 days)	Small number of beneficiaries affected
Nov 06	Older Sedative Hypnotics	-	0	0	0	0	Not applicable	No medications moved to non-formulary status
Aug 06	TZDs	-	0	0	0	0	Not applicable	No medications moved to non-formulary status
Aug 06	H2 Antagonists / GI protectants	-	0	0	0	0	Not applicable	No medications moved to non-formulary status
Aug 06	Antilipidemic Agents	<ul style="list-style-type: none"> Rosuvastatin (Crestor) Atorvastatin / amlodipine (Caduet) 	44,078	851	36,133	6,921	1 Feb 07 (90 days)	Small number of beneficiaries affected

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification
				MTF	Retail	Mail Order		
May 06	Antiemetics	<ul style="list-style-type: none"> Dolasetron (Anzemet) 	852	14	668	170	27 Sept 06 (60 days)	Small number of beneficiaries affected, and acute nature of treatment (e.g., chemotherapy)
May 06 update for new drugs Nov 06	Contraceptive Agents	<ul style="list-style-type: none"> EE 30 mcg / levonorgestrel 0.15 mg in special packaging for extended use (Seasonale) EE 25 mcg / norethindrone 0.4 mg (Ovcon 35) EE 50 mcg / norethindrone 1 mg (Ovcon 50) EE 20/30/35 mcg / norethindrone 1 mg (Estrostep Fe) EE 20 mcg/1 mg norethindrone-24 day regimen (Loestrin 24 Fe) EE 30/10 mcg/ 0.15 mg levonorgestrel for extended use (Seasonique) 	23,221 (4% of patients receiving a contraceptive)	3,128	19,249	844	24 Jan 07 (180 days)	Relatively low number of beneficiaries affected, but a high proportion are receiving Seasonale, which is packaged as a 3-month supply
Feb 06	OABs	<ul style="list-style-type: none"> tolterodine IR (Detrol) oxybutynin patch (Oxytrol) trosipium (Sanctura) 	19,118	2,596	13,471	3,051	Jan 24 07 (60 days; to coincide with Seasonal)	Small number of beneficiaries affected
				0 Rx	112 Rx	4 Rx		Recommended 60-day implementation overturned; 90-day BAP recommendation accepted
				22 Rx	3,417 Rx	64 Rx		

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification
				MTF	Retail	Mail Order		
Feb 06	Misc Anti-hypertensive Agents	<ul style="list-style-type: none"> felodipine/enalapril (Lexxel) verapamil/trandolapril (Tarka) 	5,946	336	4,472	1,138	26 July 06 (90 days)	Recommended 60-day implementation overturned; 90-day BAP recommendation accepted
Feb 06	GABA-analogs	<ul style="list-style-type: none"> pregabalin (Lyrica) 	30,649	1,120	27,566	1,963	28 Jun 06 (60 days)	Small number of beneficiaries affected
Nov 05	Alzheimer's Drugs	<ul style="list-style-type: none"> tacrine (Cognex) 	5	0	3	2	19 Apr 06 (90 days)	Small number of beneficiaries affected
Nov 05	Nasal Corticosteroid Agents	<ul style="list-style-type: none"> beclomethasone dipropionate (Beconase AQ, Vancenase AQ) budesonide (Rhinocort Aqua) triamcinolone (Nasacort AQ) 	96,999	13,556	73,381	10,062	19 Apr 06 (90 days)	Substantial number of beneficiaries affected
Nov 05	Macrolide/Ketolide Antibiotics	<ul style="list-style-type: none"> azithromycin 2 gm (Zmax) tellithromycin (Ketek) 	Total number not provided; antibiotics are used to treat acute infections				22 Mar 06 (60 days)	Small number of beneficiaries affected, Medication used to treat acute (not chronic) infections not likely to require therapy change
Nov 05	Antidepressants	<ul style="list-style-type: none"> paroxetine HCl CR (Paxil) fluoxetine 90 mg for weekly administration (Prozac Weekly) fluoxetine in special packaging for PMDD (Sarafem) escitalopram (Lexapro) duloxetine (Cymbalta) bupropion extended release (Wellbutrin XL) 	182,916	52,624	118,582	11,710	19 Jul 06 (180 days)	Substantial number of beneficiaries affected
Aug 05	Alpha Blockers for BPH	<ul style="list-style-type: none"> tamsulosin (Flomax) 	89,926	26,692	47,674	15,560	15 Feb 06 (120 days)	Substantial number of beneficiaries affected

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification
				MTF	Retail	Mail Order		
Aug 05	CCBs	<ul style="list-style-type: none"> amlodipine (Norvasc) isradipine IR (Dynacirc) isradipine ER (Dynacirc CR) nicardipine IR (Cardene, generics) nicardipine SR (Cardene SR) verapamil ER (Verelan) verapamil ER for bedtime dosing (Verelan PM, Covera HS) diltiazem ER for bedtime dosing (Cardizem LA) 	274,616	133,794	101,345	39,477	15 Mar 06 (150 days)	Substantial number of beneficiaries affected
Aug 05	ACE Inhibitors & ACE Inhibitor / HCTZ Combinations	<ul style="list-style-type: none"> moexipril (Univasc), moexipril / HCTZ (Uniretic) perindopril (Aceon) quinapril (Accupril) quinapril / HCTZ (Accuretic) ramipril (Altace) 	158,101	77,159	57,982	22,959	16 Feb 06 (120 days)	Substantial number of beneficiaries affected
May 05	PDE-5 Inhibitors	<ul style="list-style-type: none"> sildenafil (Viagra) tadalafil (Cialis) 	128,007	55,161	49,850	22,996	12 Oct 05 (90 days)	Substantial number of beneficiaries affected
May 05 updated for new drug Nov 06	Topical Antifungals*	<ul style="list-style-type: none"> econazole ciclopirox oxiconazole (Oxistat) sertaconazole (Ertaczo) sulconazole (Exelderm) 	49,743	14,266	33,430	2,047	17 Aug 05 (30 days)	Medication used to treat acute (not chronic) infections not likely to require therapy change
May 05	MS-DMDs	<ul style="list-style-type: none"> miconazole 0.25%, zinc oxide 15%, white petrolatum 82.35% (Vusion) 	581 (Apr 06-Oct 06) (UU not applicable)	7	571	3	21 Feb 07 (60 days)	Small numbers of beneficiaries affected
		-	0	0	0	0	Not applicable	No medications moved to non-formulary status

Meeting	Drug Class	Non-Formulary Medications	Total Beneficiaries Affected (# of patients affected)	Beneficiaries Affected by POS			Implementation Plan First Wednesday X days after the decision date	Justification
				MTF	Retail	Mail Order		
Feb 05	ARBs	<ul style="list-style-type: none"> • eprosartan (Teveten) • eprosartan/HCTZ (Teveten HCT) 	2,184	13	1,644	527	17 Jul 05 (90 days)	Recommended 30-day implementation overturned; 90-day BAP recommendation accepted
Feb 05	PPIs	<ul style="list-style-type: none"> • esomeprazole (Nexium) 	138,739	6,691	117,520	14,528	17 Jul 05 (90 days)	Substantial number of beneficiaries affected

BCF = Basic Core Formulary; ECF = Extended Core Formulary; ESI = Express-Scripts, Inc; MN = Medical Necessity; TMOP = TRICARE Mail Order Pharmacy; TRRx = TRICARE Retail Pharmacy program; UF = Uniform Formulary
CR = controlled release; ER = extended release; IR = immediate release; LA = long-acting; SR = sustained release; XL = extended release
5-ARI = 5-Alpha Reductase Inhibitors; ADHD = Attention Deficit Hyperactivity Disorder; ACE Inhibitors = Angiotensin Converting Enzyme Inhibitors; ARBs = Angiotensin Receptor Blockers; BPH = Benign Prostatic Hypertrophy; CCBs = Calcium Channel Blockers; EE = ethinyl estradiol; GI = gastrointestinal; GABA = gamma-aminobutyric acid; H2 = Histamine-2 receptor; HCTZ = hydrochlorothiazide; LIP-1s = Antilipidemic I; LIP-2s = Antilipidemic II; MAOI = Monoamine Oxidase Inhibitor; MS-DMDs = Multiple Sclerosis Disease-Modifying Drugs; OABs = Overactive Bladder Medications;
PDE-5 Inhibitors = Phosphodiesterase-5 inhibitors; PMDD = Premenstrual Dysmorphic Disorder; PPIs = Proton Pump Inhibitors; SODAS = spheroidal oral drug absorption system; TZDs = thiazolidinediones

*The topical antifungal drug class excludes vaginal products and products for onychomycosis (e.g., ciclopirox topical solution [Penlac])